Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

clobetasol (Rx)Brand and Other Names:Temovate, Temovate E, more...Cormax, Clobex, Clobex Spray, Clarelux, Cormax Ointment, Cormax Scalp Application, Olux, Olux-E, Olux-E Foam

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

cream, gel, ointment, shampoo, liquid, lotion, solution, spray, or foam

  • 0.05%
more...

Corticosteroid-responsive Dermatoses

Cream/foam: Apply thin layer to affected areas q12hr and rub in gently and completely; not to exceed 50 g/week

Corticosteroid-responsive Dermatoses of the Scalp

Foam: Apply to affected area in scalp q12hr for up to 2 weeks; not to exceed 50 g or 50 mL/week

Scalp Psoriasis

Shampoo: Apply thin film to dry scalp qDay; leave in place for 15 min; add water, lather, and then rinse thoroughly

Mild to Moderate Plaque-type Psoriasis of Nonscalp Areas

Foam: Apply to affected area in scalp q12hr for up to 2 weeks; not to exceed 50 g/week

Moderate to Severe Plaque-type Psoriasis

Emollient/cream/lotion: Apply to affected area in scalp q12hr for up to 2 weeks if area is less than 10% of the body surface area; not to exceed 50 g/week

Spray: Apply by spraying onto affected area q12hr; rub into skin; should not be used for more than 4 weeks

Dosage Forms & Strengths

cream, gel, ointment, shampoo, liquid, lotion, solution, spray, or foam

  • 0.05%
more...

Corticosteroid-responsive Dermatoses

<12 years

  • Safety & efficacy not established

>12 years

  • Cream/foam: Apply thin layer to affected areas q12hr and rub in gently and completely; not to exceed 50 g/week

Corticosteroid-responsive Dermatoses of the Scalp

<12 years

  • Safety & efficacy not established

>12 years

  • Foam: Apply to affected area in scalp q12hr for up to 2 weeks; not to exceed 50 g or 50 mL/week

Scalp Psoriasis

<12 years

  • Safety & efficacy not established

>12 years

  • Shampoo: Apply thin film to dry scalp qDay; leave in place for 15 min; add water, lather, and then rinse thoroughly

Mild to Moderate Plaque-type Psoriasis of Nonscalp Areas

<12 years

  • Safety & efficacy not established

>12 years

  • Foam: Apply to affected area in scalp q12hr for up to 2 weeks; not to exceed 50 g/week
Next

Adverse Effects

Frequency Not Defined

Skin atrophy

Striae

Burning

Cracking/fissuring of the skin

Erythema

Folliculitis

Irritation

Numbness

Pruritus

Stinging

Hypopigmentation (high potency topical steroids)

Intracranial hypertension reported in children with use of topical formulation

Adrenal suppression, Cushing syndrome, hyperglycemia

Acneform lesions

Secondary infection

Pigmentation changes

HPA suppression (with higher potency used >2 weeks); doses as low as 2 g/day can produce HPA suppression

Previous
Next

Warnings

Contraindications

Viral, fungal, or tubercular skin lesions

Hypersensitivity

Ophthalmic use

Cautions

Chronic topical corticosteroid therapy may interfere with growth and development in children

May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, especially in younger children or patients receiving high doses for prolonged periods

Allergic contact dermatitis reported with use; diagnosed by failure to heal rather than clinical exacerbation

Kaposi's sarcoma reported with prolonged corticosteroid treatment

Percutaneous absorption of corticosteroids may cause manifestations of Cushing's syndrome

Use lower potency in children; may absorb proportionally larger amounts after topical application and may cause systemic effects

Previous
Next

Pregnancy & Lactation

Pregnancy category: C

Lactation: Excretion in milk unknown; use with caution

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Mechanism of Action

Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; and reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation

Pharmacokinetics

Absorption: Percutaneously

Metabolism: Hepatic

Excretion: Urine and feces

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.